Cagrilintide vs Mod GRF 1-29
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | Mod GRF 1-29 |
|---|---|---|
| Dose Range | 300 mcg–4.5 mg | 100 mcg–200 mcg |
| Frequency | Less than daily | 3x daily |
| Cycle Length | 26–68 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. |
| Best For |
What They Have in Common
Cagrilintide, Mod GRF 1-29 are both commonly used for:
Key Differences
Unique to Mod GRF 1-29:
Which Has Stronger Evidence?
- Fat Loss: Cagrilintide has stronger research support.
| Goal | Cagrilintide | Mod GRF 1-29 |
|---|---|---|
| Fat Loss | high | medium |
Key Studies
Cagrilintide
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
The lancet. Diabetes & endocrinology, 2026
- A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.
Nature metabolism, 2026
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
The New England journal of medicine, 2025
Ready to Learn More?
Looking for trusted sources?